All In Biotech

Drug Trial Radar · NCT06383767

A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer

A Open-label, Randomized, Multicenter Phase III Study of ESG401 Versus Investigator's Choice Chemotherapy in Patients With Locally Advanced or Metastatic HR+/HER2- Breast Cancer Who Had Failed at Least One Line of Chemotherapy

Last checked: Nov 19, 2026Latest source record: Jun 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 378 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

378

Planned (sponsor's estimate)

Start

Jul 11, 2024

Primary completion

Jun 30, 2027

Study completion Jul 31, 2028

Sponsor

Lead sponsor
Qilu Pharmaceutical Co., Ltd.Industry
Sponsor type
Industry
First posted
Apr 25, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of this study is to evaluate the efficacy and safety of ESG401 in patients with unresectable locally advanced or metastatic HR+/HER2- breast cancer.

Conditions

  • Metastatic Breast Cancer

Interventions

  • ESG401Drug

    IV infusion on day 1,8, and 15 of each 28 day cycle

  • Eribulin, capecitabine, gemcitabine or vinorelbine (Treatment of Physician's Choice)Drug

    Eribulin, capecitabine, gemcitabine or vinorelbine

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free survival (PFS) assessed by IRC per RECIST 1.1Time frame: Up to 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.